Cargando…
Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy
The adoptive transfer of CAR-T cells, which are modified T cells expressing chimeric antigen receptors (CARs), to target B cell maturation antigen (BCMA) has demonstrated impressive results in treating relapsed/refractory multiple myeloma. Although BCMA CAR-T therapy induces certain complications in...
Autores principales: | Qiu, Lei, Zhu, Feng, Wei, Guoqing, Wu, Wenjun, Yang, Luxin, Hu, Yongxian, Huang, He |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society for Regenerative Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232090/ https://www.ncbi.nlm.nih.gov/pubmed/32455157 http://dx.doi.org/10.1016/j.reth.2020.03.005 |
Ejemplares similares
-
Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2020) -
Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2021) -
Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
por: Zu, Cheng, et al.
Publicado: (2022) -
Idiopathic thrombocytopenic purpura coexisting with polycythemia vera
por: Niscola, Pasquale, et al.
Publicado: (2011) -
Multiple myeloma with concurrent immune thrombocytopenic purpura
por: Sarfraz, Humaira, et al.
Publicado: (2020)